Population Pharmacokinetic Meta-Analysis of Trabectedin (ET-743, Yondelis ® ) in Cancer Patients

By Juan Jose Perez-Ruixo   Zannikos Peter  

Clinical Pharmacokinetics, Vol. 46, Iss. 10, 2007-01 ,pp. : 867-884

Adis International

Access to resources Recommend Favorite

Trabectedin: ET 743, Ecteinascidin 743, Yondelis

By  

Drugs in R&D, Vol. 4, Iss. 1, 2003-01 ,pp. : 75-81

Adis International

Access to resources Recommend Favorite

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

By Beumer Jan-Hendrik   Buckle Tessa   Ouwehand Mariet   Franke Niels   Lopez-Lazaro Luis   Schellens Jan   Beijnen Jos   Tellingen Olaf  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766

By Adis International Limited  

Drugs in R&D, Vol. 7, Iss. 5, 2006-01 ,pp. : 317-328

Adis International

Access to resources Recommend Favorite

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug

By Brandon Esther   Sparidans Rolf   Guijt Kees-Jan   Löwenthal Sjoerd   Meijerman Irma   Beijnen Jos   Schellens Jan  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 3-14

Springer Publishing Company

Access to resources Recommend Favorite